Grail
Researchers Stress Specificity of Grail Multi-Cancer Detection Test in Response to Study Criticism
Premium
The authors of a commentary said they view recent study results as informative, though limited, regarding the test's performance in prostate cancer.
Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.
Grail to Cut Headcount by 30 Percent in Restructuring, Reports 43 Percent Q2 Revenue Rise
Reporting its financial results as a separate company for the first time since its spinoff from Illumina, Grail said the restructuring will save it $27 million this year.
Oncologists Contend With Practice Implications of Emerging Multi-Cancer Detection Tests
At ASCO's annual meeting, audience questions on hypothetical cases revealed that oncologists are already having to make decisions about MCED use despite lingering unanswered questions.
UK NHS Declines to Accelerate Grail Galleri Implementation Following Early Data Review
The decision comes just weeks after Grail officials touted the decision as a potential positive catalyst for the firm as it prepares to be divested by Illumina.